Significantly improving outcomes by enhancing adaptive immune responses
Historically, the problem with immunotherapy has been the lack of an effective adaptive immune response. The challenge: how to generate a therapeutic response while limiting exposure to toxic adjuvants or constitutively activated T cells. Vedantra develops methods to precisely target the adaptive immune system, using its natural processes to expand immune cells that destroy infected or cancerous cells without harming normal tissues.
Born from the Irvine Lab at MIT, Vedantra’s platform technologies are able to deliver agents directly to the antigen-presenting cells of the lymph nodes. As demonstrated in Nature Materials, Science Translational Medicine, and Nature, getting the right molecules to the right place reduces adjuvant toxicity while enhancing immune responses against an array of antigens in both cancer and infectious disease.
We engineer solutions that harness the immune system's powerful potential to combat some of the world's most devastating health problems.